Eyepoint’s pivotal results for its wet age-related macular degeneration drug Duravyu underperformed expectations in an Eyepoint-sponsored Phase 3 program, with patients failing to maintain vision on less frequent injections than a standard regimen. The miss hit the primary endpoint tied to injection interval durability and sharply increased approval timeline uncertainty for Duravyu. The setback sent Eyepoint’s stock tumbling and complicated the company’s regulatory path for an extended-dosing eye therapy in wet AMD. The trial disappointment also shifted attention to Ocular Therapeutix, whose competing approach is slated for an FDA filing later this year. The readthrough underscores how dosing durability—rather than initial response alone—remains the central bar for next-wave wet AMD entrants targeting less frequent intravitreal treatment.